TCI Gene Inc. was established in 2011, with the concept of preventive medicine, early intervention and improvement of the health of individuals, families and all mankind. TCI Gene Inc. is the first to promote the concept of Predict, Prevent, Personal Treatment personalized health management strategies of precision preventive medicine. Through genetic testing to evaluate your innate physical condition, TCI Gene provides customized precision medicine and patented health care to create a golden shield for health. The company’s services include: genetic testing, gut microbiota testing, virus testing, cell experiments, production of adipose-derived stem cell preparations for the treatment of degenerative arthritis and chondral injury, production of natural killer cells for cancer treatment, and personalized genetic health foods.
2011 | The company was established with a paid-in capital of $10,000,000 NTD |
2013 | “DNA Chip for testing obesity” won the Gold Prize and Special Award at the Invention & New Product Exposition (INPEX) |
2014 | “DNA Chip for Testing Wellness Issues” won the Gold Prize at the International Exhibition of Inventions of Geneva |
2015 | “R1 Biochip” won the Gold Prize and Special Award at the Invention & New Product Exposition (INPEX) |
2020 | “QVS-96S, the fully automated detection integration system” won the Gold Prize and Special Award at the 2020 International Invention and Trade Expo (London) and 2020 iCAN International Invention Innovation Competition |
2020 | “QVS-96S, the fully automated detection integration system” won the 17th National Innovation Award – Enterprise Innovation Award |
2022 | Listed on the strategic new board of emerging markets |
2022 | Switched to listing on the general board of emerging markets |
2023 | LDTs cardiovascular pharmacogenomic test accreditation |